HomeInsightsStock Comparison

Cipla Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Cipla Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jul 06, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1513 as of 04 Jul 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 22.1 on March 2025 . This represents a CAGR of 0.08% over 6 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 116434 crore on March 2025 . This represents a CAGR of 22.71% over 6 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The revenue of Cipla Ltd for the Mar '25 is ₹ 7019 crore as compare to the Dec '24 revenue of ₹ 7294 crore. This represent the decline of -3.78% The revenue of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 3267 crore as compare to the Dec '24 revenue of ₹ 3418 crore. This represent the decline of -4.41%.
  • The ebitda of Cipla Ltd for the Mar '25 is ₹ 1827 crore as compare to the Dec '24 ebitda of ₹ 2210 crore. This represent the decline of -17.35% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 199.89 crore as compare to the Dec '24 ebitda of ₹ 631.36 crore. This represent the decline of -68.34%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1225 crore over 8 quarters. This represents a CAGR of 10.87% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 4.38 crore over 8 quarters. This represents a CAGR of -84.09% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.05 % on March 2025 . This represents a CAGR of 9.87% over 6 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
  • The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.

Cipla Ltd News Hub

News

Cipla to conduct board meeting

Cipla will hold a meeting of the Board of Directors of the Company on 25 July 2025. Powere...

Read more

02 Jul 2025 10:19

News

Cipla allots 43,396 equity shares under ESOP

Cipla has allotted 43,396 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

27 Jun 2025 11:02

News

Cipla Ltd spurts 0.42%, up for fifth straight session

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1517.2, up ...

Read more

11 Jun 2025 13:00

News

Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen

Jay Precision Pharmaceuticals, subsidiary of Cipla, has completed acquisition of 26% stake...

Read more

29 May 2025 18:48

News

Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorpo...

Read more

29 May 2025 18:50

News

Cipla to convene AGM

Cipla announced that the 89th Annual General Meeting(AGM) of the company will be held on 1...

Read more

14 May 2025 15:08

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharmaceuticals Ltd spurts 1.6%, rises for fifth straight session

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoti...

Read more

04 Jul 2025 13:00

News

Glenmark Pharmaceuticals Ltd up for third straight session

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quotin...

Read more

02 Jul 2025 13:05

News

Glenmark Pharmaceuticals launches TEVIMBRA' in India

Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA' (tislelizumab) in India following t...

Read more

24 Jun 2025 10:53

News

Glenmark pharma's US facility receives five observations after USFDA GMP inspection

According to a regulatory filing by the company, the USFDA conducted a good manufacturing ...

Read more

18 Jun 2025 09:51

News

Glenmark Pharmaceuticals Ltd soars 0.98%, rises for fifth straight session

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoti...

Read more

11 Jun 2025 13:00

News

Glenmark receives DCGI approval to launch oncology drug BRUKINSA in India

Glenmark Pharmaceuticals has announced the upcoming launch of zanubrutinib in India follow...

Read more

09 Jun 2025 11:04

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Cipla Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Cipla Ltd is 122,246 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 51,685 Cr

What are the key factors driving the stock performance of Cipla Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Cipla Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Glenmark Pharmaceuticals Ltd?

As of July 6, 2025, the Cipla Ltd stock price is INR ₹1513.5. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹1831.5.

How do dividend payouts of Cipla Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Cipla Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions